Can finasteride or buspirone increase liver enzyme levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Effect of Finasteride and Buspirone on Liver Enzyme Levels

Yes, both finasteride and buspirone can increase liver enzyme levels, with buspirone posing a significantly higher risk, particularly in patients with pre-existing liver disease.

Buspirone and Liver Enzymes

Buspirone has a well-documented impact on liver enzymes and metabolism:

  • Buspirone undergoes extensive hepatic metabolism, with significantly altered pharmacokinetics in patients with liver disease 1
  • In patients with cirrhosis, buspirone's area under the curve (AUC) is approximately 16 times higher than in normal subjects (55 ng·ml⁻¹·h vs 3.5 ng·ml⁻¹·h) 1
  • Maximum concentration (Cmax) is also substantially higher in patients with liver disease (18.8 ng·ml⁻¹ vs 1.2 ng·ml⁻¹ in normal subjects) 1
  • The elimination half-life of buspirone is nearly doubled in patients with hepatic impairment compared to healthy individuals 2

Clinical Implications for Buspirone

  • Buspirone should be used with caution in patients with liver disease due to its altered pharmacokinetics 1
  • Monitoring of liver enzymes is advisable when starting buspirone, particularly in patients with pre-existing liver conditions
  • Dose adjustment may be necessary in patients with hepatic impairment due to the substantially higher drug exposure

Finasteride and Liver Enzymes

Finasteride has a less significant impact on liver enzymes:

  • Finasteride is primarily metabolized by CYP3A4 in the liver 3
  • Unlike buspirone, finasteride has not been widely associated with significant liver enzyme elevations
  • Finasteride metabolism can be affected by drugs that induce or inhibit CYP3A4 enzymes 3

Monitoring Recommendations

For patients taking either medication:

  • Consider baseline liver function tests before initiating therapy, especially with buspirone

  • For buspirone:

    • More vigilant monitoring is recommended, particularly in patients with pre-existing liver disease
    • Consider liver enzyme testing after 4-6 weeks of therapy
    • Dose reduction may be necessary in patients with hepatic impairment
  • For finasteride:

    • Routine monitoring of liver enzymes is generally not required in patients without liver disease
    • Consider periodic monitoring in patients with pre-existing liver conditions or those taking other hepatotoxic medications

Risk Factors for Liver Enzyme Elevations

Factors that increase the risk of liver enzyme elevations with either medication include:

  • Pre-existing liver disease
  • Concomitant use of other hepatotoxic medications
  • Alcohol consumption
  • Metabolic syndrome components 4

When to Discontinue Medication

Consider discontinuation of either medication if:

  • ALT/AST levels exceed 3× upper limit of normal (ULN)
  • ALT/AST levels exceed 5× ULN or signs of liver dysfunction appear 4
  • Patient develops symptoms of hepatitis (fatigue, nausea, right upper quadrant pain, jaundice)

Conclusion

While both medications can potentially affect liver enzymes, buspirone poses a significantly higher risk, particularly in patients with pre-existing liver disease. Finasteride's effect on liver enzymes appears to be minimal in most patients. Appropriate monitoring and dose adjustments should be implemented based on individual patient risk factors and clinical response.

References

Research

Buspirone pharmacokinetics in patients with cirrhosis.

British journal of clinical pharmacology, 1987

Research

Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.

Drug metabolism and disposition: the biological fate of chemicals, 1995

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.